Genome-wide associations for benign prostatic hyperplasia reveal a genetic correlation with serum levels of PSA.
Average rating
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Star rating
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Authors
Gudmundsson, JuliusSigurdsson, Jon K
Stefansdottir, Lilja
Agnarsson, Bjarni A
Isaksson, Helgi J
Stefansson, Olafur A
Gudjonsson, Sigurjon A
Gudbjartsson, Daniel F
Masson, Gisli
Frigge, Michael L
Stacey, Simon N
Sulem, Patrick
Halldorsson, Gisli H
Tragante, Vinicius
Holm, Hilma
Eyjolfsson, Gudmundur I
Sigurdardottir, Olof
Olafsson, Isleifur
Jonsson, Thorvaldur
Jonsson, Eirikur
Barkardottir, Rosa B
Hilmarsson, Rafn
Asselbergs, Folkert W
Geirsson, Gudmundur
Thorsteinsdottir, Unnur
Rafnar, Thorunn
Thorleifsson, Gudmar
Stefansson, Kari
Issue Date
2018-11-08
Metadata
Show full item recordCitation
Genome-wide associations for benign prostatic hyperplasia reveal a genetic correlation with serum levels of PSA. 2018, 9(1):4568 Nat CommunAbstract
Benign prostatic hyperplasia and associated lower urinary tract symptoms (BPH/LUTS) are common conditions affecting the majority of elderly males. Here we report the results of a genome-wide association study of symptomatic BPH/LUTS in 20,621 patients and 280,541 controls of European ancestry, from Iceland and the UK. We discovered 23 genome-wide significant variants, located at 14 loci. There is little or no overlap between the BPH/LUTS variants and published prostate cancer risk variants. However, 15 of the variants reported here also associate with serum levels of prostate specific antigen (PSA) (at a Bonferroni corrected P < 0.0022). Furthermore, there is a strong genetic correlation, rDescription
To access publisher's full text version of this article, please click on the hyperlink in Additional Links field or click on the hyperlink at the top of the page marked DownloadAdditional Links
https://www.nature.com/articles/s41467-018-06920-9ae974a485f413a2113503eed53cd6c53
10.1038/s41467-018-06920-9
Scopus Count
Collections
Related articles
- A genetic variant near GATA3 implicated in inherited susceptibility and etiology of benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS).
- Authors: Na R, Helfand BT, Chen H, Conran CA, Crawford SE, Hayward SW, Tammela TLJ, Hoffman-Bolton J, Zheng SL, Walsh PC, Schleutker J, Platz EA, Isaacs WB, Xu J
- Issue date: 2017 Aug
- Non-steroidal anti-inflammatory drug use and the risk of benign prostatic hyperplasia-related outcomes and nocturia in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.
- Authors: Sutcliffe S, Grubb Iii RL, Platz EA, Ragard LR, Riley TL, Kazin SS, Hayes RB, Hsing AW, Andriole GL, Urologic Diseases in America Project.
- Issue date: 2012 Oct
- The role of BPH, lower urinary tract symptoms, and PSA levels on erectile function of Brazilian men who undergo prostate cancer screening.
- Authors: Antunes AA, Srougi M, Dall'oglio MF, Vicentini F, Paranhos M, Freire GC
- Issue date: 2008 Jul
- Sexually transmitted infections, benign prostatic hyperplasia and lower urinary tract symptom-related outcomes: results from the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial.
- Authors: Breyer BN, Huang WY, Rabkin CS, Alderete JF, Pakpahan R, Beason TS, Kenfield SA, Mabie J, Ragard L, Wolin KY, Grubb RL 3rd, Andriole GL, Sutcliffe S
- Issue date: 2016 Jan
- The utility of serum prostatic-specific antigen in the management of men with benign prostatic hyperplasia.
- Authors: Roehrborn CG
- Issue date: 2008 Dec